Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses - Wikidata - awgldk - TriplyDB

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses

http://www.wikidata.org/entity/Q24631361

about

Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells Genetic, immunological, and pharmacological strategies to generate improved oncolytic viruses Avian Paramyxovirus: A Brief Review Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.Oncolytic viruses: From bench to bedside with a focus on safety.Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer Safety and clinical usage of newcastle disease virus in cancer therapy Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.Oncolysis by paramyxoviruses: preclinical and clinical studies.Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Use of attenuated paramyxoviruses for cancer therapy.Recent advances in oncolytic virus design.Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Newcastle disease virus: a promising agent for tumour immunotherapy.Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.Oncolytic vaccines.Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies.Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.Oncolytic Immunotherapy for Treatment of Cancer.Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.Therapeutic potential of oncolytic Newcastle disease virus: a critical review.Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.Novel oncolytic viral therapies in patients with thoracic malignancies.Rescue of recombinant Newcastle disease virus from cDNA.Cell-type-specific innate immune response to oncolytic Newcastle disease virus.Construction of a minigenome rescue system for Newcastle disease virus strain Italien.Oncolytic viruses from the perspective of the immune system.Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity.Tumor Restrictions to Oncolytic Virus.

P2860

Q24602706-B1E80F6E-FCD7-4557-B8AD-FCAC52C1F2A2 Q26859879-280A617C-399D-4F56-A5D3-DE20E3598B19 Q28261383-11DA6A80-B175-4B97-8BFB-83725053B752 Q33906116-20F958B2-B562-41BC-9545-D7653591E234 Q33933665-D6FA0052-53BC-4D94-AC94-2F863A19E28A Q34028464-99B3B750-A137-4AE6-B6B1-5CA3C7AA6A33 Q34044071-50B471D5-E4EE-4ED0-ADD8-D5F3581B07A5 Q34110261-64946DB6-C377-4BDA-8A88-7C6F550E3E79 Q34227719-487E3D60-2550-43AF-BE93-E1F363747804 Q35050645-2C8E0111-4AFD-4EBE-A792-6749C07F776F Q35498222-DF3C696C-401C-4634-BB95-8135B7320805 Q35665220-46E54CDC-92BA-428C-A0E4-527C846AE5F7 Q35699080-D64B0702-8B94-423D-98ED-67F3BB2B464B Q35750051-E5C339F5-AD68-48F3-9825-A60D2DF7F631 Q35861933-B7CCC05D-712E-4FA9-AB2A-7AB4D643C6FF Q35861936-183908E0-D3AF-4B30-977F-9875BED9F03A Q36308045-370036C7-3CBF-4684-9DC1-72607F7BFAEB Q36611663-1A963008-4E06-44B1-9418-D41F27F346A6 Q36753953-6617D116-1203-4A04-A30E-D1B983398C95 Q37564490-F868BF6E-5CF6-4FB1-B84F-D425204D17EE Q37810599-A2300519-D669-4D0C-8078-E469873A2687 Q37865172-9EC9B87F-5B55-4EDA-9A07-0E1E9A0D075A Q37933439-662D2D50-240D-411C-B233-B3F3689B75A5 Q37972664-243717B0-77C0-43F3-8DAE-B7CBA5285022 Q37990940-4E352FB3-45F7-4CCE-BF5F-FF79F019E447 Q38152474-545830A3-749E-4E72-A284-44F0CF1DF4E4 Q38259582-7348BABB-167F-4AA9-9084-43532D1701F6 Q38264652-84340C50-7A2A-4CE2-88B0-96E3C577A408 Q38599166-F07BB878-431E-4E86-87CD-3311EEDB0197 Q38848223-8C42B282-5D7B-4A17-AE2A-3F46C4A16F14 Q38860227-C7819448-24EE-47E6-A24C-A8EEF6F96F18 Q38924554-F961F2E9-3D17-4D43-8DA8-929C88E3F716 Q39037822-0693F482-F874-4474-83ED-0BD34CA12D41 Q39067827-D01F5E77-F709-49A4-81B7-3F1C15AFDB34 Q39074984-1D7AB661-1495-46DC-BC75-27153A738A79 Q39312501-A5FA59DE-3EBF-4801-9461-A690E7E39493 Q39612067-0A394DAE-12AB-4E37-A490-CC1D42FCB66B Q39974038-EFCE6302-6240-4388-89F6-C096A037EA86 Q40063602-70E2A527-F61B-480F-BCA9-D3C82C28D003 Q51846287-213DC9D7-19D9-4931-B3BD-45704EA12CCF

P2860

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses

http://www.wikidata.org/entity/Q24631361

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Enhancement of oncolytic prope ...... llular innate immune responses

@ast

Enhancement of oncolytic prope ...... llular innate immune responses

@en

Enhancement of oncolytic prope ...... llular innate immune responses

@nl

type

label

Enhancement of oncolytic prope ...... llular innate immune responses

@ast

Enhancement of oncolytic prope ...... llular innate immune responses

@en

Enhancement of oncolytic prope ...... llular innate immune responses

@nl

prefLabel

Enhancement of oncolytic prope ...... llular innate immune responses

@ast

Enhancement of oncolytic prope ...... llular innate immune responses

@en

Enhancement of oncolytic prope ...... llular innate immune responses

@nl

P1433

Q24631361-9EE5D819-F04C-4796-8755-91046B2331D5

P1476

Q24631361-23ECA296-5210-40DB-ABFB-828E1EA994FD

P2093

Q24631361-36E08BB0-829F-4B0E-A142-52E7E79AEF3D

Q24631361-9171E882-459C-4B28-BDAB-D6299C363715

Q24631361-9D74F73F-F994-4179-B437-52A8DEC904AD

Q24631361-A1661F4E-29F8-4C0A-B338-1B25E370BD9A

Q24631361-ECE7C124-3228-4DB9-A27F-987BF4D94D34

P2860

Q24631361-01195501-0826-454D-BF24-E316FE5AC8CB

Q24631361-0328F212-19D4-4743-AE45-2593849CC83C

Q24631361-033029A2-CEB8-43A0-9C57-DE690A1BEC03

Q24631361-04DD9C76-10FB-41BA-8A61-95BDC2A40F3F

Q24631361-06933D2C-1471-4F7F-B730-C92BD471CB55

Q24631361-0E2BBDD5-0112-41F0-9D26-B72C6AC8FA85

Q24631361-140169DD-3D09-41C1-9C68-344AAE6F0BE2

Q24631361-1AF8F2DE-6C1E-4C89-937B-28E4EBCEA672

Q24631361-27B2DEF5-D2B0-47A6-98A6-04A174DE69EA

Q24631361-2E9EDF89-6DD7-460A-B003-E1F769A7E965

P304

Q24631361-6FBD28B8-7C88-42ED-8F1C-8878D327D430

P31

Q24631361-C15CB736-0371-495B-958F-0C3D0345A53B

P356

Q24631361-59E3F758-6341-49F3-9C09-DB89E4A652F3

P407

Q24631361-8CCF15C3-F1D4-42D4-8A43-A38B2DD454F9

P433

Q24631361-FA6A2D1E-1621-4944-886A-FF9BB5359F22

P478

Q24631361-6A0FC0E1-D97F-4F95-8353-F9592CBDE7D7

P50

Q24631361-3BA3B128-9C25-45D8-8136-A87EA1DA8F53

Q24631361-80C0657D-C4A3-465F-B7C8-77A7074CD0BA

Q24631361-E4994E53-EF4D-48D0-B1DF-8A6731ED8B62

Q24631361-FB123E0D-6E79-4DD6-8351-2EA8D433910F

P577

Q24631361-569BFC5D-0A51-4327-8726-93039682B520

P5875

Q24631361-45157D26-243F-4D5C-B293-63667D8F273F

P698

Q24631361-5984A7BA-FCF2-4585-A20A-5E0AD6BCD7AE

P921

Q24631361-5F28BDBC-86AF-40A0-8BA7-0AC549639004

Q24631361-A1D2053C-D4D6-4E2F-A9AC-691E7EC44E90

P932

Q24631361-9E4B4F96-6954-4C4F-B92F-A0C30D8EEFDE

P356

P1433

Molecular Therapy

P1476

Enhancement of oncolytic prope ...... llular innate immune responses

@en

P2093

Adam Vigil

http://www.w3.org/2001/XMLSchema#string

Dmitriy Zamarin

http://www.w3.org/2001/XMLSchema#string

Gang Sheng

http://www.w3.org/2001/XMLSchema#string

Kaitlyn Kelly

http://www.w3.org/2001/XMLSchema#string

Yuman Fong

http://www.w3.org/2001/XMLSchema#string

P2860

Sialobiology of Influenza: Molecular Mechanism of Host Range Variation of Influenza Viruses

Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy

A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire

Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3' end processing of cellular pre-mRNAS

Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems

Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein

Newcastle disease virus (NDV): brief history of its oncolytic strains.

P304

697-706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2008.286

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Adolfo García-Sastre

Luis Martinez-Sobrido

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23999549

http://www.w3.org/2001/XMLSchema#string

P698

19209145

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2835121

http://www.w3.org/2001/XMLSchema#string